2-imidazol-1-ylmethyl-1-methyl-1H-benzoimidazole | 26558-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-imidazol-1-ylmethyl-1-methyl-1H-benzoimidazole
• 英文别名: 2-(Imidazol-1-yl)methyl-1-methyl-1H-benzimidazole；2-(1H-imidazol-1-ylmethyl)-1-methyl-1H-benzimidazole；2-(imidazol-1-ylmethyl)-1-methylbenzimidazole
• CAS: 26558-95-2
• 化学式: C₁₂H₁₂N₄
• mdl: MFCD01951912
• 分子量: 212.254
• InChiKey: KCIKCTBVFQVVKM-UHFFFAOYSA-N

物化性质

• 沸点：
  479.7±28.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  35.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0003560A2

  公开（公告）日：1979-08-22

  Pharmaceutical formulations comprising an imidazole (or pharmaceutically acceptable salt thereof) of formula: wherein (i) A is an aliphatic hydrocarbon residue of from 1 to 4 carbon atoms and R is a naphthyl, tetrahydronaphthyl, heterocyclyl, arylthio, arylalkylthio, aryloxy, arylalkyloxy, arylhydroxymethylene, arylcarbonyl, arylalkylcarbonyl, alkyloxy, alkylthio or a substituted cycloalkyl or cycloalkenyl group or (ii) A is a -S02- group and R is aryl or heterocyclyl or (iii) A is a chemical bond and R is a heterocyclyl or substituted phenyl group, or (iv) A is an aliphatic hydrocarbon residue of from 1 to 3 carbon atoms and R is a halophenyl group. Some of these imidazoles and salts are novel. Methods of preparing the imidazoles are disclosed. The imidazoles and their salts are useful in the treatment or prophylaxis of thrombo-embolic conditions.

  药物制剂，包含式中的咪唑（或其药学上可接受的盐）： 其中 (i) A 是 1 至 4 个碳原子的脂族烃残基，R 是萘基、四氢萘基、杂环基、芳硫基、芳烷硫基、芳氧基、芳烷氧基、芳羟甲基、芳羰基、芳烷基羰基、烷氧基、烷硫基或取代的环烷基或环烯基，或 (ii) A 是-S02-基团，R 是芳基或杂环基，或 (iii) A 是化学键，R 是杂环基或取代苯基，或 (iv) A 是 1 至 3 个碳原子的脂肪烃残基，R 是卤代苯基。 其中一些咪唑和盐是新型的。 这些咪唑的制备方法已经公开。咪唑及其盐类可用于治疗或预防血栓栓塞。
• Fused imidazole compounds, processes for the preparation thereof and pharmaceutical compositions containing them
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0125756A2

  公开（公告）日：1984-11-21

  The present invention provides new fused imidazole compounds of the formula: wherein A is a lower alkylene radical, R' is a hydrogen or halogen atom or a lower alkyl or lower alkoxy radical, R2 is a hydrogen atom or a lower alkyl, cyclo(lower)alkyl, pyridyl, ar(lower)alkyl, which may be substituted by halogen, or aryl radical, which may be substituted by lower alkyl, lower alkoxy, hydroxy or halogen, R3 is an N-containing unsaturated heterocyclic radical, which may be substituted by lower alkyl or amino, and Y is =C- or =N-, and the pharmaceutically-acceptable salts thereof; and processes for the preparation thereof, as well as pharmaceutical compositions comprising them. These new compounds and the salts thereof are useful as anti-ulcer agents.

  本发明提供了式如下的新的融合咪唑化合物： 其中A是低级亚烷基，R'是氢原子或卤素原子或低级烷基或低级烷氧基，R2是氢原子或可被卤素取代的低级烷基、环（低）烷基、吡啶基、芳（低）烷基或芳基、可被低级烷基、低级烷氧基、羟基或卤素取代的芳基，R3 是可被低级烷基或氨基取代的含 N 的不饱和杂环基，Y 是 =C- 或 =N-，以及它们的药学上可接受的盐；及其制备工艺，以及包含它们的药物组合物。 这些新化合物及其盐类可用作抗溃疡剂。
• US4416895A
  申请人：——

  公开号：US4416895A

  公开（公告）日：1983-11-22
• US4528195A
  申请人：——

  公开号：US4528195A

  公开（公告）日：1985-07-09
• US4563455A
  申请人：——

  公开号：US4563455A

  公开（公告）日：1986-01-07